Improvement of CART Therapies by Chemical Biology Approaches

A special issue of Biology (ISSN 2079-7737).

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3612

Special Issue Editors

Department of Chemical Engineering, Villanova University, Villanova, PA 19085, USA
Interests: upstream and downstream bio(pharmaceutical) processing; particularly for cell therapy products
Poseida Therapeutics, San Diego, CA, USA
Interests: process development for the cell and gene therapy products via viral and non viral gene modifications

Special Issue Information

Dear Colleagues,

Cell therapies have demonstrated their efficacy in treating or being curative in severe diseases, chronic diseases, and cancers. This Special Issue is devoted to exploring avenues to improve the efficacy of cell therapy products as well as improvements to the manufacturing process, with particular emphasis on CAR products intended for immunotherapy applications.  These cells are exposed to a viral vector that integrates the coding sequence for a chimeric antigen receptor (CAR) that allows for binding to target cancer cells. There is significant and problematic patient-to-patient variability in the blood entering the current autologous CART processes, which might be managed better by screening with improved assays potentially identifying relevant biomarkers. Novel use of CRISPR and other gene-editing techniques may potentially give rise to cell lines that are capable of avoiding the body’s host immune response, resulting in allogenic products with more general use and likely lower costs. This issue will cover chemical and biological approaches leading to process and product improvements that include better understanding and/or manipulation of the CAR gene, cellular genetics, and metabolism, as well as non-cellular process inputs such as Lentivirus. Lentivirus construct and manufacturing approaches that produce an improved Lentivirus particle are covered as well.

Prof. Dr. William J. Kelly
Dr. Nooshie Sanaie
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell therapy
  • immunotherapy
  • CART
  • T cells
  • CD4 or CD8
  • Natural Killer (NK) cells
  • lentivirus
  • autologous

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1013 KiB  
Review
Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products
by Chen-Yuan Kao, Jason A. Mills, Carl J. Burke, Barry Morse and Bruno F. Marques
Biology 2023, 12(5), 677; https://doi.org/10.3390/biology12050677 - 04 May 2023
Cited by 1 | Viewed by 3144
Abstract
Cytokines and other growth factors are essential for cell expansion, health, function, and immune stimulation. Stem cells have the additional reliance on these factors to direct differentiation to the appropriate terminal cell type. Successful manufacturing of allogeneic cell therapies from induced pluripotent stem [...] Read more.
Cytokines and other growth factors are essential for cell expansion, health, function, and immune stimulation. Stem cells have the additional reliance on these factors to direct differentiation to the appropriate terminal cell type. Successful manufacturing of allogeneic cell therapies from induced pluripotent stem cells (iPSCs) requires close attention to the selection and control of cytokines and factors used throughout the manufacturing process, as well as after administration to the patient. This paper employs iPSC-derived natural killer cell/T cell therapeutics to illustrate the use of cytokines, growth factors, and transcription factors at different stages of the manufacturing process, ranging from the generation of iPSCs to controlling of iPSC differentiation into immune-effector cells through the support of cell therapy after patient administration. Full article
(This article belongs to the Special Issue Improvement of CART Therapies by Chemical Biology Approaches)
Show Figures

Figure 1

Back to TopTop